Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome

World Journal of Gastroenterology

Volumn 20, Issue 39, 2014, Pages 14172-14184

  Kelley, Carly E ^a   Brown, Ann J ^a   Diehl, Anna Mae ^a   Setji, Tracy L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fatty liver; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Polycystic ovary syndrome

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ADIPOCYTOKINE; ANDROGEN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; OBETICHOLIC ACID; PENTOXIFYLLINE; PROBIOTIC AGENT; URSODEOXYCHOLIC ACID;

ADIPOSE TISSUE; ADOLESCENT; APOPTOSIS; BARIATRIC SURGERY; CARDIOVASCULAR RISK; DISEASE COURSE; GENETICS; HERBAL MEDICINE; HIGH RISK PATIENT; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LEAN BODY WEIGHT; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PREVALENCE; REVIEW; RISK ASSESSMENT; SCREENING; SLEEP DISORDERED BREATHING; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR;

CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84910112544     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i39.14172     Document Type: Review

References (131)

1. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-3004 [PMID: 12799409 DOI: 10.1001/jama.289.22.3000]
2. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a casecontrol study. Hepatology 2000; 32: 689-692 [PMID: 11003611 DOI: 10.1053/jhep.200.17894]
3. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, Rybicki L, McCullough AJ. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560-565 [PMID: 9647594]
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 [PMID: 10348825]
5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152 DOI: 10.1056/NEJMra011775]
7. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 565-580 [PMID: 19818305 DOI: 10.1016/j.cld.2009.07.003]
8. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719 [PMID: 7489979 DOI: 10.1016/0270-9139(95)90196-5]
9. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-2047 [PMID: 14499785 DOI: 10.1111/j.1572-0241.2003.07659.x]
10. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941 DOI: 10.1053/j.gastro.2005.04.014]
11. Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, Sørensen HT. Prognosis of patients with a diagnosis of fatty liver - a registry-based cohort study. Hepatogastroenterology 2003; 50: 2101-2104 [PMID: 14696473]
12. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-612 [PMID: 18682312 DOI: 10.1016/j.jhep.2008.06.018]
13. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-798 [PMID: 18752331 DOI: 10.1002/hep.22429]
14. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]
15. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749 [PMID: 15181052 DOI: 10.1210/jc.2003-032046]
16. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41 [PMID: 20591140 DOI: 10.1186/1741-7015-8-41]
17. Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Ginecol 2004; 56: 1-6 [PMID: 14973405]
18. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25 [PMID: 14711538 DOI: 10.1016/j.fertnstert.2003.10.004]
19. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245 [PMID: 16940456 DOI: 10.1210/jc.2006-0178]
20. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-551 [PMID: 19910321 DOI: 10.1093/humrep/dep399]
21. Brown AJ, Tendler DA, McMurray RG, Setji TL. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract 2005; 11: 319-324 [PMID: 16191492 DOI: 10.4158/EP.11.5.319]
22. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 494-497 [PMID: 15705403 DOI: 10.1016/j.fertnstert.2004.08.020]
23. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1741-1747 [PMID: 16492691 DOI: 10.1210/jc.2005-2774]
24. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007; 5: 496-501 [PMID: 17287148 DOI: 10.1016/j.cgh.2006.10.010]
25. Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, Arrese M. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47: 412-417 [PMID: 17560682 DOI: 10.1016/j.jhep.2007.04.012]
26. Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009; 24: 243-247 [PMID: 19215335 DOI: 10.1111/j.1440-1746.2008.05740.x]
27. Hossain N, Stepanova M, Afendy A, Nader F, Younossi Y, Rafiq N, Goodman Z, Younossi ZM. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol 2011; 46: 479-484 [PMID: 21114431 DOI: 10.3109/00365521.2010.539251]
28. Barfield E, Liu YH, Kessler M, Pawelczak M, David R, Shah B. The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2009; 22: 318-322 [PMID: 19576817 DOI: 10.1016/j.jpag.2009.03.003]
29. Michaliszyn SF, Lee S, Tfayli H, Arslanian S. Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile. Fertil Steril 2013; 100: 1745-1751 [PMID: 24034940 DOI: 10.1016/j.fertnstert.2013.08.015]
30. Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166: 2081-2086 [PMID: 17060537 DOI: 10.1001/archinte.166.19.2081]
31. Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, Piaditis G, Kaltsas G. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 2010; 93: 1220-1226 [PMID: 19171337 DOI: 10.1016/j.fertnstert.2008.12.008]
32. Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009; 8: 199-206 [PMID: 19671519 DOI: 10.14310/horm.2002.1236]
33. Baranova A, Tran TP, Afendy A, Wang L, Shamsaddini A, Mehta R, Chandhoke V, Birerdinc A, Younossi ZM. Molecular signature of adipose tissue in patients with both nonalcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med 2013; 11: 133 [PMID: 23721173 DOI: 10.1186/1479-5876-11-133]
34. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-363 [PMID: 20159883 DOI: 10.1093/humupd/dmq001]
35. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49: 600-607 [PMID: 18672311 DOI: 10.1016/j.jhep.2008.06.012]
36. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51: 1947-1953 [PMID: 18762907 DOI: 10.1007/s00125-008-1135-4]
37. Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, Kilpatrick ES, Atkin SL. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2014; 80: 843-849 [PMID: 23746214 DOI: 10.1111/cen.12258]
38. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379 [PMID: 11826411]
39. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007; 91: 1125-1149, ix [PMID: 17964913 DOI: 10.1016/j.mcna.2007.06.001]
40. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007; (1): CD005166 [PMID: 17253544 DOI: 10.1002/14651858.CD005166.pub2]
41. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-823 [PMID: 22966992 DOI: 10.1111/apt.12046]
42. Wicks IP, Cooke BE, Allen R, Bertouch JV. Aortic incompetence associated with severe rheumatoid arthritis. Med J Aust 1987; 146: 317-320 [PMID: 3821639 DOI: 10.3390/ijms14020704]
43. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-1266 [PMID: 1397698 DOI: 10.2337/diabetes.41.10.1257]
44. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174 [PMID: 2670645 DOI: 10.2337/diabetes.38.9.1165]
45. Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, Cuthbertson DJ. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 2012; 97: 3709-3716 [PMID: 22837189 DOI: 10.1210/jc.2012-1382]
46. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013; 28: 777-784 [PMID: 23315061 DOI: 10.1093/humrep/des463]
47. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 801-814 [PMID: 21251033 DOI: 10.1111/j.1365-2036.2011.04579.x]
48. Karoli R, Fatima J, Chandra A, Gupta U, Islam FU, Singh G. Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci 2013; 6: 9-14 [PMID: 23869143 DOI: 10.4103/0974-1208.112370]
49. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010; 25: 212-220 [PMID: 19887498 DOI: 10.1093/humrep/dep380]
50. Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 2010; 26: 39-46 [PMID: 20001571 DOI: 10.3109/09513590903184084]
51. Targher G, Solagna E, Tosi F, Castello R, Spiazzi G, Zoppini G, Muggeo M, Day CP, Moghetti P. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest 2009; 32: 695-700 [PMID: 19542757 DOI: 10.3275/6375]
52. Pauli JM, Raja-Khan N, Wu X, Legro RS. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med 2011; 28: 1445-1454 [PMID: 21950959 DOI: 10.1111/j.1464-5491.2011.03460.x]
53. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62: 904-910 [PMID: 3514651 DOI: 10.1210/jcem-62-5-904]
54. Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1990; 70: 699-704 [PMID: 2106527 DOI: 10.1210/jcem-70-3-699]
55. Geffner ME, Kaplan SA, Bersch N, Golde DW, Landaw EM, Chang RJ. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril 1986; 45: 327-333 [PMID: 3512314 DOI: 10.1097/0 0006254-198742050-00014]
56. Nagamani M, Van Dinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 1986; 154: 384-389 [PMID: 3511712 DOI: 10.1016/0002-9378(86)90676-9]
57. Goldman MH, Scheraldi CA, Soule WC. Ovarian hyperthecosis associated with fatty liver disease. Am J Obstet Gynecol 1987; 156: 1239-1240 [PMID: 3578443 DOI: 10.1016/0002-9378(87)90154-2]
58. Croston GE, Milan LB, Marschke KB, Reichman M, Briggs MR. Androgen receptor-mediated antagonism of estrogendependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology 1997; 138: 3779-3786 [PMID: 9275065 DOI: 10.1210/en.138.9.3779]
59. Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN. Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 3332-3341 [PMID: 20427499 DOI: 10.1210/jc.2009-2698]
60. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967 [PMID: 12809815 DOI: 10.1111/j.1572-0241.2003.07486.x]
61. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007; 133: 1814-1820 [PMID: 18054554 DOI: 10.1053/j.gastro.207.08.077]
62. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, Sansonetti N, Opolon P. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998; 27: 1213-1219 [PMID: 9581673]
63. Arun J, Clements RH, Lazenby AJ, Leeth RR, Abrams GA. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006; 16: 1351-1358 [PMID: 17059746 DOI: 10.1381/096089206778663715]
64. Lee K, Sung JA, Kim JS, Park TJ. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev 2009; 25: 150-155 [PMID: 19117027 DOI: 10.1002/dmrr.924]
65. Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007; 92: 3470-3475 [PMID: 17579193 DOI: 10.1210/jc.2007-0746]
66. Yeh SH, Chiu CM, Chen CL, Lu SF, Hsu HC, Chen DS, Chen PJ. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int J Cancer 2007; 120: 1610-1617 [PMID: 17230529 DOI: 10.1002/ijc.22479]
67. Yeh SH, Chang CF, Shau WY, Chen YW, Hsu HC, Lee PH, Chen DS, Chen PJ. Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. Cancer Res 2002; 62: 4346-4351 [PMID: 12154039]
68. Yu L, Nagasue N, Yamaguchi M, Chang YC. Effects of castration and androgen replacement on tumour growth of human hepatocellular carcinoma in nude mice. J Hepatol 1996; 25: 362-369 [PMID: 8895016 DOI: 10.1016/S0168-8278(96)80123-1]
69. Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S, Chang C. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 2008; 135: 947-955, 955.e1-e5 [PMID: 18639551 DOI: 10.1053/j.gastro.2008.05.046]
70. Tock L, Carneiro G, Togeiro SM, Hachul H, Pereira AZ, Tufik S, Zanella MT. Obstructive sleep apnea predisposes to nonalcoholic Fatty liver disease in patients with polycystic ovary syndrome. Endocr Pract 2014; 20: 244-251 [PMID: 24246334 DOI: 10.4158/EP12366.OR]
71. Tanné F, Gagnadoux F, Chazouillères O, Fleury B, Wendum D, Lasnier E, Lebeau B, Poupon R, Serfaty L. Chronic liver injury during obstructive sleep apnea. Hepatology 2005; 41: 1290-1296 [PMID: 15915459 DOI: 10.1002/hep.20725]
72. Mishra P, Nugent C, Afendy A, Bai C, Bhatia P, Afendy M, Fang Y, Elariny H, Goodman Z, Younossi ZM. Apnoeichypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int 2008; 28: 1080-1086 [PMID: 18647236 DOI: 10.1111/j.1478-3231.2008.01822.x]
73. Aron-Wisnewsky J, Minville C, Tordjman J, Lévy P, Bouillot JL, Basdevant A, Bedossa P, Clément K, Pépin JL. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012; 56: 225-233 [PMID: 21703181 DOI: 10.1016/j.jhep.2011.04.022]
74. Sookoian S, Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg 2013; 23: 1815-1825 [PMID: 23740153 DOI: 10.1007/s11695-13-0981-4]
75. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112 [PMID: 16447287 DOI: 10.1002/hep.20973]
76. Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K, Canbay A. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 343-348 [PMID: 19906783 DOI: 10.1210/jc.2009-1834]
77. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001; 80: 230-239 [PMID: 11322387 DOI: 10.1078/0171-9335-00154]
78. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-1078 [PMID: 19585618 DOI: 10.1002/hep.23050]
79. Dai R, Yan D, Li J, Chen S, Liu Y, Chen R, Duan C, Wei M, Li H, He T. Activation of PKR/eIF2α signaling cascade is associated with dihydrotestosterone-induced cell cycle arrest and apoptosis in human liver cells. J Cell Biochem 2012; 113: 1800-1808 [PMID: 22228470 DOI: 10.1002/jcb.24051]
80. Ma RC, Liu KH, Lam PM, Cheung LP, Tam WH, Ko GT, Chan MH, Ho CS, Lam CW, Chu WC, Tong PC, So WY, Chan JC, Chow CC. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: 799-807 [PMID: 21190980 DOI: 10.1210/jc.2010-1608]
81. Kral JG, Schaffner F, Pierson RN, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42: 548-551 [PMID: 8492707 DOI: 10.1016/0026-0495(93)90210-F]
82. Borruel S, Fernández-Durán E, Alpañés M, Martí D, Alva-rez-Blasco F, Luque-Ramírez M, Escobar-Morreale HF. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2013; 98: 1254-1263 [PMID: 23386652 DOI: 10.1210/jc.2012-3698]
83. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep 2011; 11: 179-184 [PMID: 21424395 DOI: 10.1007/s11892-011-0189-8]
84. Mannera˚s-Holm L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G, Hellström M, Lönn L, Olivecrona G, Stener-Victorin E, Lönn M. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 2011; 96: E304-E311 [PMID: 21084397 DOI: 10.1210/jc.2010-1290]
85. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 70-75 [PMID: 15663921 DOI: 10.1007/s11892-005-0071-7]
86. Corbould A, Dunaif A. The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome. Metabolism 2007; 56: 716-722 [PMID: 17445549 DOI: 10.1016/j.metabol.2006.12.021]
87. Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33: 812-841 [PMID: 22829562 DOI: 10.1210/er.2012-1003]
88. Yilmaz M, Bukan N, Demirci H, Oztürk C, Kan E, Ayvaz G, Arslan M. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 246-252 [PMID: 19408174 DOI: 10.1080/09513590802653833]
89. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010; 9: 402-409 [PMID: 21057159]
90. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 Suppl 1: 63-69 [PMID: 20844903 DOI: 10.1007/s00535-010-0311-8]
91. Shimizu I, Kohno N, Tamaki K, Shono M, Huang HW, He JH, Yao DF. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol 2007; 13: 4295-4305 [PMID: 17708600]
92. Tarantino G, Valentino R, Di Somma C, D'Esposito V, Passaretti F, Pizza G, Brancato V, Orio F, Formisano P, Colao A, Savastano S. Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clin Endocrinol (Oxf) 2013; 78: 447-453 [PMID: 22805002 DOI: 10.1111/j.1365-2265.2012.04500.x]
93. Neel BA, Sargis RM. The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes 2011; 60: 1838-1848 [PMID: 21709279 DOI: 10.2337/db11-0153]
94. Lind L, Lind PM. Can persistent organic pollutants and plastic-associated chemicals cause cardiovascular disease? J Intern Med 2012; 271: 537-553 [PMID: 22372998 DOI: 10.1111/j.1365-2796.2012.02536.x]
95. Diamanti-Kandarakis E, Christakou C, Marinakis E. Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Des 2012; 18: 270-282 [PMID: 22229564 DOI: 10.2174/138161212799040457]
96. Tsushima Y, Endo K. Spleen enlargement in patients with nonalcoholic fatty liver: correlation between degree of fatty infiltration in liver and size of spleen. Dig Dis Sci 2000; 45: 196-200 [PMID: 10695635]
97. Gangale MF, Miele L, Lanzone A, Sagnella F, Martinez D, Tropea A, Moro F, Morciano A, Ciardulli A, Palla C, Pompili M, Cefalo C, Grieco A, Apa R. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 2011; 75: 520-527 [PMID: 21569072 DOI: 10.1111/j.1365-2265.2011.04093.x]
98. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-145 [PMID: 9005748 DOI: 10.7326/0003-4819-126-2-199701150-00008]
99. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 475-485 [PMID: 24574716 DOI: 10.3748/wpg.v20.i2.475]
100. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-589 [PMID: 17661414 DOI: 10.1002/hep.21768]
101. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10 [PMID: 12093239 DOI: 10.7326/0003-4819-137-1-200207020-00006]
102. Ciotta L, Pagano I, Stracquadanio M, Formuso C. [Polycystic ovarian syndrome incidence in young women with non-alcoholic fatty liver disease]. Minerva Ginecol 2011; 63: 429-437 [PMID: 21926952]
103. Carmina E. Need for liver evaluation in polycystic ovary syndrome. J Hepatol 2007; 47: 313-315 [PMID: 17624467 DOI: 10.1016/j.jhep.2007.06.009]
104. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-4592 [PMID: 24151290 DOI: 10.1210/jc.2013-2350]
105. Lerchbaum E, Gruber HJ, Schwetz V, Giuliani A, Möller R, Pieber TR, Obermayer-Pietsch B. Fatty liver index in polycystic ovary syndrome. Eur J Endocrinol 2011; 165: 935-943 [PMID: 21937505 DOI: 10.1530/EJE-11-0614]
106. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33 [PMID: 17081293 DOI: 10.1186/1471-230X-6-33]
107. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]
108. Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39: 3-14 [PMID: 24206433 DOI: 10.1111/apt.12543]
109. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-266 [PMID: 21723839 DOI: 10.1016/j.jhep.2011.06.010]
110. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011; (7): CD007506 [PMID: 21735412 DOI: 10.1002/14651858.CD007506.pub3]
111. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89: 505-522 [PMID: 18243179 DOI: 10.1016/j.fertnstert.2007.09.041]
112. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904 [PMID: 22278337 DOI: 10.1007/s00125-011-2446-4]
113. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome. BJOG 2009; 116: 1242-1250 [PMID: 19438498 DOI: 10.1111/j.1471.0528.2009.02177.x]
114. Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, Williams NI, Coney P, Legro RS. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 2011; 95: 1059-1066.e1-e7 [PMID: 21193187 DOI: 10.1016/j.fert nstert.2010.12.002]
115. Preiss D, Sattar N, Harborne L, Norman J, Fleming R. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract 2008; 62: 1337-1343 [PMID: 18565127 DOI: 10.1111/j.1742-1241.2008.01825.x]
116. Domecq JP, Prutsky G, Mullan RJ, Sundaresh V, Wang AT, Erwin PJ, Welt C, Ehrmann D, Montori VM, Murad MH. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab 2013; 98: 4646-4654 [PMID: 24092830 DOI: 10.1210/jc.2013-2374]
117. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118 [PMID: 15356308 DOI: 10.1056/NEJMra041001]
118. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN; PCOS/Troglitazone Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-1632 [PMID: 11297595 DOI: 10.1210/jcem.86.4.7375]
119. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN; PCOS/Troglitazone Group. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 932-937 [PMID: 12749433 DOI: 10.1016/S0015-0282(02)04914-2]
120. Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2014; 81: 523-528 [PMID: 24256515 DOI: 10.1111/cen.12369]
121. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007; (1): CD004996 [PMID: 17253535 DOI: 10.1002/14651858.CD004996.pub3]
122. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-1668 [PMID: 21521847 DOI: 10.1001/jama.2011.520]
123. Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842-3848 [PMID: 19622617 DOI: 10.1210/jc.2009-0870]
124. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56: 944-951 [PMID: 22023985 DOI: 10.1016/j.jhep.2011.08.018]
125. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19: 6911-6918 [PMID: 24187469 DOI: 10.3748/wjg.v19.i40.6911]
126. Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, Hazen SL, Feldstein AE. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012; 56: 1291-1299 [PMID: 22505276 DOI: 10.1002/hep.25778]
127. Shi KQ, Fan YC, Liu WY, Li LF, Chen YP, Zheng MH. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Mol Biol Rep 2012; 39: 9715-9722 [PMID: 22718512 DOI: 10.1007/s11033-012-1836-0]
128. Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Identifier NCT01265498, The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial (FLINT); 2010 Dec 21 [cited 2014 Apr 07]; [about 4 screens]. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01265498?term=nct01265498&rank=1
129. Duleba AJ, Pawlczyk L. Should we use statins in treatment of polycystic ovary syndrome? Expert Rev Endocrinol Metab 2009; 4: 209-211 [DOI: 10.1586/eem.09.1]
130. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 1396-1402 [PMID: 18986848 DOI: 10.1016/j.cgh.2008.08.012]
131. Gomez-Meade CA, Lopez-Mitnik G, Messiah SE, Arheart KL, Carrillo A, de la Cruz-Muñoz N. Cardiometabolic health among gastric bypass surgery patients with polycystic ovarian syndrome. World J Diabetes 2013; 4: 64-69 [PMID: 23772274 DOI: 10.4239/wjd.v4.i3.64]